<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864899</url>
  </required_header>
  <id_info>
    <org_study_id>UW21-005</org_study_id>
    <nct_id>NCT04864899</nct_id>
  </id_info>
  <brief_title>Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR)</brief_title>
  <acronym>R-COVID-CMR</acronym>
  <official_title>Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study that aims to clinical significance of subclinical&#xD;
      myocardial involvement in recovered COVID-19 patients using cardiovascular magnetic&#xD;
      resonance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to:&#xD;
&#xD;
        1. Determine the extent of myocardial involvement of COVID-19, as assessed by&#xD;
           Cardiovascular Magnetic Resonance (CMR), 2 weeks after patient recovery, at 3-month post&#xD;
           discharge and at 1-year post discharge.&#xD;
&#xD;
        2. Correlate these myocardial characteristics to biventricular structure, function, blood&#xD;
           biomarkers of inflammation, clinical symptoms, and functional capacity at all time&#xD;
           points.&#xD;
&#xD;
        3. Follow up recovered COVID-19 patients beyond the end of this study to assess for hard&#xD;
           outcomes such as death, heart failure hospitalization, cardiac arrest and ventricular&#xD;
           tachycardia/ fibrillation.&#xD;
&#xD;
      Recovered COVID-19 patients and age and gender matched controls subjects will be recruited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The extent of myocardial involvement, as assessed by CMR tissue characterisation (T1/ T2/ ECV/ LGE), change from 2 weeks after patient recovery, at 3-months post discharge and at 1-year post discharge.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The correlation of these myocardial characteristics to biventricular structure at all time-points.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The correlation of these myocardial characteristics to biventricular function (CMR cine/strain) at all time-points.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The correlation of these myocardial characteristics to blood biomarkers of inflammation at all time-points.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The correlation of these myocardial characteristics to clinical symptoms at all time-points.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The correlation of these myocardial characteristics to functional capacity (6 minute walk test) at all time-points.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follow-up patients beyond the end of this study to assess for hard outcomes such as death.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up patients beyond the end of this study to assess for hard outcomes such as heart failure hospitalisation.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up patients beyond the end of this study to assess for hard outcomes such as cardiac arrest.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up patients beyond the end of this study to assess for hard outcomes such as ventricular tachycardia/ fibrillation.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Covid19</condition>
  <condition>Viral Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>Recovered COVID-19 patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Recovered non-COVID-19 viral respiratory infections patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Age and gender matched controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Magnetic Resonance Imaging (CMR)</intervention_name>
    <description>Imaging</description>
    <arm_group_label>Age and gender matched controls</arm_group_label>
    <arm_group_label>Recovered COVID-19 patients</arm_group_label>
    <arm_group_label>Recovered non-COVID-19 viral respiratory infections patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood investigation</description>
    <arm_group_label>Age and gender matched controls</arm_group_label>
    <arm_group_label>Recovered COVID-19 patients</arm_group_label>
    <arm_group_label>Recovered non-COVID-19 viral respiratory infections patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>6-minute walk test</intervention_name>
    <description>Correlating the cardiac MRI parameters with functional capacity</description>
    <arm_group_label>Age and gender matched controls</arm_group_label>
    <arm_group_label>Recovered COVID-19 patients</arm_group_label>
    <arm_group_label>Recovered non-COVID-19 viral respiratory infections patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Recovered COVID-19 patients&#xD;
&#xD;
        Definition of recovered COVID-19 patient:&#xD;
&#xD;
          -  COVID-19 diagnosis = established by a positive reverse transcription polymerase chain&#xD;
             reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 [SARS-CoV2] and&#xD;
             recovered from COVID-19.&#xD;
&#xD;
          -  Recovery = based on two criteria: (1) two negative nasopharyngeal swab RT-PCR results&#xD;
             &gt;24 hours apart and (2) absence of fever and improvement in respiratory symptoms.&#xD;
&#xD;
               -  Recovered non-COVID-19 patients with viral respiratory infections confirmed with&#xD;
                  viral polymerase chain reaction testing AND with a confirmed negative COVID-19&#xD;
                  RT-PCR test.&#xD;
&#xD;
               -  Age and gender matched controls with no cardiac risk factors, not on cardiac&#xD;
                  medications, no history of myocardial infarction, heart failure or myocarditis,&#xD;
                  negative COVID-19 RT-PCR test and negative COVID-19 antibodies test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous myocardial infarction or myocarditis unrelated to COVID-19 infection&#xD;
&#xD;
          -  History of heart failure unrelated to COVID-19 infection&#xD;
&#xD;
          -  Presence of pacemakers or implantable cardiac defibrillators&#xD;
&#xD;
          -  Any contraindication for CMR testing&#xD;
&#xD;
          -  Renal impairment with eGFR &lt;45ml/min/1.73m2&#xD;
&#xD;
          -  Limited life expectancy &lt;1 year, for example due to pulmonary disease, cancer or&#xD;
             significant hepatic failure&#xD;
&#xD;
          -  Refusal or inability to sign an informed consent.&#xD;
&#xD;
          -  Potential for non-compliance towards the requirements in the trial protocol&#xD;
             (especially the medical treatment) or follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming-Yen NG, BMBS</last_name>
    <phone>22554524</phone>
    <email>myng2@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Yen Ng, BMBS</last_name>
      <phone>22554524</phone>
      <email>myng2@hku.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Ng Ming-Yen</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

